J&J single shot sees 66% efficacy in moderate COVID-19, 85% in severe cases; shares fall

Johnson & Johnson noticed its shares fall 4% in early buying and selling on the information that its one-shot COVID-19 vaccine noticed 66% efficacy in average to extreme illness, rising to 85% in extreme illness. That 66% headline hit J&J’s … Read more